Immunome (IMNM) traded down -0.56 % during a 24 hours period ending at 09:50 PM Central Europe on Tuesday 27th. One Immunome stock can currently be bought for about USD 18.77 on popular exchanges. Current supply of Immunome stocks is 113.7 mn. Immunome has a current market capitalization of USD 2.1 bn and approximately USD 16.3 mn worth of Immunome was traded on exchanges in the last 24 hours. Since last month end, Immunome has traded -17.48 % down. Simple moving average of last 200 days is at USD 22.54. The highest price of past 52 weeks was recorded at USD 30.06 on 08/19/2026. 52 weeks low was at USD 14.64 on 11/07/2025.

Here is how related stocks have performed in the past 24 hours:

  • Innospec (IOSP) traded up 0.55 % and now trades at USD 99.92. Current market capitalisation for Innospec is USD 2.4 bn. Current price/earnings ratio for Innospec is 20.1.

  • Brookdale Senior Living (BKD) traded down -3.17 % and now trades at USD 9.54. Brookdale Senior Living has a market capitalisation of USD 2.4 bn.

  • Transmedics (TMDX) traded down -0.16 % and now trades at USD 69.88. Current market capitalisation for Transmedics is USD 2.4 bn. Transmedics has a current price to earnings ratio of 17.87.

  • Gabelli & Income Tr (GDV-PK) traded down -0.33 % and now trades at USD 16.5. Gabelli & Income Tr has a market capitalisation of USD 2.5 bn. Gabelli & Income Tr has a current price to earnings ratio of 5.19. GABELLI DIVIDEND & INCOME TR has received a neutral assessment in recent market commentary. Analysts note that the fund has maintained a steady outlook, with no significant shift in its dividend strategy. While no major corporate actions were highlighted, the fund’s performance appears to align with broader market trends. Observers have noted that the fund’s exposure to dividend‑yielding securities remains consistent, supporting its income‑focused mandate. Overall, the review suggests a stable positioning for the fund amid a generally unchanged economic environment.

  • Clover Health Investments (CLOV) traded down -0.87 % and now trades at USD 4.63. Current market capitalisation for Clover Health Investments is USD 2.4 bn. Clover Health Investments, Corp. announced that its Interim Chief Financial Officer will speak at the upcoming UBS Global Healthcare Conference on November 9, 2026. The presentation will be streamed live and recorded for later viewing on the company’s investor relations website. Clover Health, a physician‑enablement technology firm, focuses on expanding access to high‑quality healthcare for Medicare beneficiaries, particularly seniors who historically face limited options. Its strategy relies on a software platform that aggregates patient data to support clinical decision‑making and improve outcomes, especially through early detection and management of chronic diseases. The company offers Medicare Advantage plans and extends its data‑driven platform to external providers via a subsidiary, aiming to enhance patient outcomes and reduce costs nationwide.

About Immunome

Immunome, Inc. is a biotechnology company based in Exton, Pennsylvania, United States. The company specializes in developing and commercializing novel therapeutic antibodies and medicines for treating various diseases. Immunome serves patients residing in the state of Pennsylvania. You can find more information about the company and its activities on their website, which is www.immunome.com . The company’s stock is traded on the Nasdaq stock exchange.